PCM
FENC icon

Potomac Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Potomac Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Buy
224,400
+129,300
+136% +$998K 1.2% 24
2025
Q4 		$732K Buy
+95,100
New +$781K 0.59% 39

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Potomac Capital Management's FENC Position: Q1 2026 in Review

Potomac Capital Management increased its Fennec Pharmaceuticals (FENC) stake by 136% in Q1 2026, buying an estimated $998K and bringing the position to 224,400 shares worth $1.38M. The position accounts for 1.2% of the portfolio, ranked #24.

Potomac Capital Management first reported a position in FENC in Q4 2025 and has held it in 2 quarters since. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Potomac Capital Management held 224,400 shares of Fennec Pharmaceuticals worth $1.38M as of Q1 2026.
  • Potomac Capital Management bought 129,300 Fennec Pharmaceuticals shares in Q1 2026, an estimated $998K.
  • Fennec Pharmaceuticals made up 1.2% of Potomac Capital Management's portfolio in Q1 2026, its #24 holding.
  • Potomac Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Potomac Capital Management's 13F filing for Q1 2026, filed 14 May 2026.